雷卢戈利克斯加恩扎胺治疗转移性激素敏感前列腺癌:一个病例报告
Alastair Thomson1, Lucinda Gunn1, Deborah Victor1
1Oncology Department, Sunrise Centre, Royal Cornwall Hospital, Truro, Cornwall, UK.
Research and reports in urology
|October 14, 2024
概括
口服Relugolix与恩扎胺结合,有效降低了前列腺癌患者的前列腺特异性抗原 (PSA) 水平. 这种组合疗法耐受性良好,在11个月内显示持续PSA降低.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 瑞卢戈力克斯是一种口服释放性腺激素的激素受体对抗剂,在英国批准用于晚期前列腺癌.
- 有限的临床经验存在于口服relugolix和口服恩扎胺的组合.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Drugs for Treatment of Diarrhea-Predominant IBS
151
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
151


